Abivax S.A.
ABVX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001956827
No open-market purchases or sales by Abivax S.A. insiders were filed in the last 90 days; 303 institutions reported holding it in 13F filings for Q2 2026, worth $7.18B in total; Maverick Capital is the only superinvestor holding it.
Other share classesAAVXF
Q3 2024 vs. Q2 2024
How the institutions holding Abivax S.A. changed between Q2 2024 and Q3 2024.
All holders in Q3 2024All holders in Q2 2024
| Measure | Q2 2024 | Q3 2024 | Change |
|---|---|---|---|
| Holders | 38 | 40 | +2 |
| Shares | 28.1M | 27.4M | −715.0K (−2.5%) |
| Value | $371.6M | $312.8M | −$58.8M (−15.8%) |
New holders (4)
Institutions that held Abivax S.A. at the end of Q3 2024 but not at the end of Q2 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Soleus Capital Management, L.P. | 125,000 | $1.44M | 0.12% |
| Marshall Wace, LLP | 30,910 | $356.1K | 0.00% |
| UBS Group AG | 691 | $7.96K | 0.00% |
| Principal Securities, Inc. | 10 | $115 | 0.00% |
Sold out (2)
Institutions that held Abivax S.A. at the end of Q2 2024 and filed for Q3 2024 without it.
| Institution | Shares, Q2 2024 | Value, Q2 2024 |
|---|---|---|
| Options Solutions, LLC | 34,750 | $459.4K |
| Sandia Investment Management LP | 7,500 | $99.2K |